- Home
- BCLI vs ADXN Comparison
BCLI vs ADXN Comparison
Compare BCLI & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- ADXN
- Stock Information
- Founded
- BCLI 2000
- ADXN 2002
- Country
- BCLI United States
- ADXN Switzerland
- Employees
- BCLI N/A
- ADXN N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- ADXN Health Care
- Exchange
- BCLI Nasdaq
- ADXN Nasdaq
- Market Cap
- BCLI 7.7M
- ADXN 8.1M
- IPO Year
- BCLI N/A
- ADXN N/A
- Fundamental
- Price
- BCLI $1.22
- ADXN $10.23
- Analyst Decision
- BCLI Strong Buy
- ADXN Strong Buy
- Analyst Count
- BCLI 1
- ADXN 1
- Target Price
- BCLI $30.00
- ADXN $30.00
- AVG Volume (30 Days)
- BCLI 3.4M
- ADXN 3.8K
- Earning Date
- BCLI 05-15-2025
- ADXN 06-17-2025
- Dividend Yield
- BCLI N/A
- ADXN N/A
- EPS Growth
- BCLI N/A
- ADXN N/A
- EPS
- BCLI N/A
- ADXN 0.08
- Revenue
- BCLI N/A
- ADXN $452,495.00
- Revenue This Year
- BCLI N/A
- ADXN $86.57
- Revenue Next Year
- BCLI N/A
- ADXN N/A
- P/E Ratio
- BCLI N/A
- ADXN $0.93
- Revenue Growth
- BCLI N/A
- ADXN N/A
- 52 Week Low
- BCLI $0.72
- ADXN $6.51
- 52 Week High
- BCLI $8.09
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- BCLI 55.90
- ADXN 73.57
- Support Level
- BCLI $1.05
- ADXN $8.08
- Resistance Level
- BCLI $1.18
- ADXN $8.20
- Average True Range (ATR)
- BCLI 0.14
- ADXN 0.23
- MACD
- BCLI 0.00
- ADXN 0.11
- Stochastic Oscillator
- BCLI 23.91
- ADXN 71.04
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.